Nuo Therapeutics, Inc. filings document a commercial-stage medical-device issuer focused on Aurix, its autologous platelet-rich plasma system for chronic wound management. The company’s regulatory record includes Current Reports on Form 8-K for material events, material agreements, capital-structure disclosures, governance matters, operating and financial results, and security-structure updates.
Proxy and annual-meeting filings describe board elections, auditor ratification, advisory executive-compensation votes, shareholder proposal procedures, and voting results. These disclosures also cover compensation arrangements, board and committee actions, common-stock matters, and public-company governance tied to commercialization of the Aurix System.
Nuo Therapeutics reported first quarter 2026 results showing higher sales and a smaller loss. Total revenue reached $1,302,115 for the three months ended March 31, 2026, up from $484,381 a year earlier, driven mainly by growth in Aurix product sales and new distribution fee revenue.
Net loss narrowed to $618,466 compared with $746,128 in the prior-year quarter, as gross profit increased while operating expenses also rose. As of March 31, 2026, Nuo reported cash of $263,827, total assets of $1,945,669, total liabilities of $3,329,532, and a stockholders’ deficit of $1,383,863.
Nuo Therapeutics reported sharply higher Q1 2026 revenue but remains loss‑making and financially constrained. Total revenue rose to about $1.3 million, up from $0.5 million a year earlier, driven by Aurix growth and new private‑label sales plus $77,941 of Smith+Nephew distribution fee revenue.
Gross profit increased to roughly $0.85 million, though gross margin slipped to about 65% as centrifuge devices were sold at near break‑even transfer prices. Operating expenses rose to about $1.3 million, reflecting higher compensation and commissions, and the company posted a net loss of $618,466, narrower than the prior‑year loss of $746,128.
Cash was only $263,827 at March 31, 2026 against current liabilities of about $1.4 million, and stockholders’ deficit widened to approximately $1.4 million. Management states there is “substantial doubt” about the ability to continue as a going concern and is relying on external capital, including a new secured note facility of up to $1.6 million with warrants, of which $1.0 million is funded.
Nuo Therapeutics, Inc. files its annual report describing a small but fast-growing chronic wound-care business built around its Aurix autologous platelet-rich plasma system. Product revenue rose from approximately $1.4 million in 2024 to $3.1 million in 2025, with total 2025 revenue of about $3.3 million including distribution fees.
The company remains unprofitable, recording a net loss of roughly $2.5 million in 2025 and warning of substantial doubt about its ability to continue as a going concern without additional capital. As of June 30, 2025, non-affiliate market value was about $41.1 million, and 48,289,296 shares of common stock were outstanding as of March 26, 2026.
Nuo highlights expanding Medicare reimbursement for Aurix, including 2026 national average rates of $2,108 per treatment in hospital outpatient settings and $1,064 in physician offices. A new U.S. distribution agreement with Smith+Nephew adds a private-label channel with minimum annual purchase commitments and up to $2.25 million in fees, but the company still faces single-supplier risks, intense competition, heavy regulatory oversight and the ongoing need for financing.
Nuo Therapeutics, Inc. disclosed that investor Paul Anthony Jacobs has a significant passive stake in its common stock. As of 01/23/2026, he beneficially owned 3,183,500 shares of common stock, including 43,500 shares issuable upon exercise of immediately exercisable warrants, representing 6.6% of the outstanding class.
Jacobs reports sole voting and dispositive power over all of these shares and states they are not held for the purpose of changing or influencing control of the company.
Nuo Therapeutics director and 10% owner Scott M. Pittman reported receiving several derivative awards in the form of warrants linked to common stock at an exercise price of $1.5 per share on January 23, 2026. The grants include Commitment Warrants, Origination Initial Warrants, Capital Initial Warrants, Origination Second Warrants, Capital Second Warrants, and Prepayment Warrants, each giving the right to buy Nuo Therapeutics common stock and expiring on January 23, 2031.
Certain Second Warrants will vest, if at all, on September 30, 2026 only if a Second Funding occurs under a Loan and Security Agreement dated January 21, 2026. The Prepayment Warrants will vest, if at all, upon a Prepayment event, but no later than December 31, 2028, and the disclosed amount reflects the maximum number of shares issuable upon such a Prepayment. The company’s Board and non-employee directors approved the loan arrangement and the related warrant and share issuances.
Nuo Therapeutics investor Scott M. Pittman reports beneficial ownership of 5,610,050 shares of common stock, or 11.6% of the company, based on 48,281,625 shares outstanding as of January 21, 2026. His holdings include 5,400,000 shares held directly, 30,050 shares issuable upon exercise of newly received warrants, and 180,000 shares underlying options.
The amendment also describes a secured loan arrangement where Pittman has loaned $200,000 to Nuo Therapeutics and committed to an additional $210,000 if requested. The notes bear interest at 10%, rising to 12% if a second closing occurs, and mature on December 31, 2028. Interest and certain prepayment fees are payable in stock warrants rather than cash, with multiple warrant series exercisable at $1.50 per share and expiring January 23, 2030, giving Pittman additional potential equity exposure through commitment, origination, capital coverage, prepayment, second-closing, and interest warrants.
Nuo Therapeutics, Inc. entered into a Loan and Security Agreement providing up to $1.6 million in secured term loans, with $1.0 million funded on January 23, 2026 and an additional $600 thousand available on September 30, 2026 if drawn. The loans bear interest at an annual rate of 10%, rising to 12% if the second tranche is funded, and mature on December 31, 2028, with principal repaid quarterly from March 31, 2027. The debt is secured by a lien on all company assets and includes mandatory prepayment upon certain equity financings, change in control events, or default, with prepayment fees paid in warrants instead of cash.
As part of this financing, Nuo issued multiple series of common stock warrants at a $1.50 exercise price, including fees, capital coverage, prepayment, and interest payment warrants, some of which vest only if the second tranche funds or if prepayment events occur. At closing the company issued warrants immediately exercisable for an aggregate of 148,000 shares and conditionally or potentially exercisable warrants for additional shares, including up to 226,000 shares in Interest Warrants tied to the full $1.6 million funding. Two significant shareholders, including director Scott M. Pittman, participated as lenders and received a portion of these warrants.
Nuo Therapeutics CEO/CFO and director David Jorden reported an insider stock option exercise. On 01/01/2026, he exercised an option to purchase 125,000 shares of Nuo Therapeutics, Inc. common stock at an exercise price of $0.40 per share using a net exercise method.
The company withheld 25,381 shares, valued at the closing price of $1.97 per share, to cover the exercise cost, and Jorden received 99,619 shares of common stock. Following these transactions, he directly beneficially owned 2,046,374 shares of Nuo Therapeutics common stock, and the reported option position was reduced to zero.
Nuo Therapeutics director reports option exercise and share withholding
A director of Nuo Therapeutics, Inc. reported transactions in the company’s common stock dated 12/17/2025. The director exercised an option to purchase 68,750 shares of common stock at an exercise price of $0.4 per share, receiving 55,000 shares on a net basis. The issuer withheld 13,750 shares of common stock underlying the option to cover the exercise price, using the closing price of $2.00 per share. Following these transactions, the director directly beneficially owned 172,654 shares of Nuo Therapeutics common stock.
Nuo Therapeutics, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on December 16, 2025. Stockholders elected four directors to the board, ratified the company’s independent auditor, and approved executive compensation on an advisory basis.
Director nominees David E. Jorden, Paul D. Mintz, Scott M. Pittman, and C. Eric Winzer each received about 33.7 million votes in favor, with only a few thousand votes withheld and 2,237,142 broker non-votes. Stockholders ratified MaloneBailey LLP as independent registered public accounting firm with 35,917,807 votes for and 12,899 against, and approved the say-on-pay proposal with 33,653,458 votes for and 40,106 against, plus 2,237,142 broker non-votes.